Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
05:11pm, Friday, 03'rd Jun 2022
Biotech investors stand to make a windfall if they make calculated bets by thoroughly researching on key catalysts that could move the stocks in a big way. The post 6 Biotech Stocks to Buy Now Ahead o
Why Is Axsome (AXSM) Down 30.3% Since Last Earnings Report?
01:33pm, Wednesday, 01'st Jun 2022
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Is This Biotech a Safe Stock to Buy?
06:15am, Saturday, 14'th May 2022
It recently got a major green light from regulators.
My Favorite Biotech
04:00pm, Friday, 13'th May 2022
Here's why three Fool.com contributors love 10x Genomics, Axsome Therapeutics, and Doximity.
Why Axsome Therapeutics Stock Got Mashed on Monday
05:46pm, Monday, 09'th May 2022
Investors were hardly impressed with the closing of a rights deal.
JAZZ Q1 Earnings Miss, Sales Robust, 2022 Guidance Raised
12:02pm, Thursday, 05'th May 2022
JAZZ's product revenues grow in the first quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. It raises guidance on strong results.
Why Axsome (AXSM) is Up 7% Despite Wider-Than-Expected Q1 Loss
12:02pm, Tuesday, 03'rd May 2022
Axsome (AXSM) reports a slightly wider-than-estimated Q1 loss. It expects to receive FDA approval for its lead candidate AXS-05 by second-quarter 2022 to treat major depressive disorder.
Axsome Therapeutics, Inc.'s (AXSM) CEO Herriot Tabuteau on Q1 2022 Results - Earnings Call Transcript
12:05pm, Monday, 02'nd May 2022
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2022 Earnings Conference Call May 2, 2022 8:00 AM ET Company Participants Mark Jacobson - Chief Operating Officer Herriot Tabuteau - Chief Executive Officer
Axsome And AXS-05: A Special Situation
02:25am, Monday, 02'nd May 2022
Current $1.2 billion valuation is unjustifiably low; conservative fundamental valuation yields $4+ billion fair value. AXS-05 has strong clinical data and a differentiated mechanism of action.
Why Axsome Therapeutics Stock Is Sinking Today
11:19am, Monday, 25'th Apr 2022
A thumbs-down from the FDA for AXS-07 in treating migraine is likely on the way.
Why Is Axsome Therapeutics (AXSM) Stock Down Today?
11:00am, Monday, 25'th Apr 2022
Axsome Therapeutics (AXSM) stock is falling hard on Monday following a report about an upcoming decision from the FDA this week. The post Why Is Axsome Therapeutics (AXSM) Stock Down Today?
Axsome Poised To Receive FDA Rejection For Its Migraine Candidate, Shares Fall
10:57am, Monday, 25'th Apr 2022
The FDA has informed that Axsome Therapeutics Inc (NASDAQ: AXSM) chemistry, manufacturing, and controls issues identified during the review of AXS-07 remain unresolved. The Company is seeking appro
Why Axsome Therapeutics Stock Is Falling Today
09:54am, Monday, 25'th Apr 2022
Axsome Therapeutics Inc (NASDAQ: AXSM) shares are trading higher Monday after the company reported it was informed by the U.S. Food and Drug Administration (FDA) that chemistry, manufacturing and co
Axsome Therapeutics to Report First Quarter 2022 Financial Results on May 2, 2022
07:00am, Monday, 25'th Apr 2022
Axsome to host conference call and webcast on Monday, May 2, 2022 at 8:00 AM Eastern Time NEW YORK, April 25, 2022 /PRNewswire/ -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical compan
The FDA Will Soon Give These 3 Healthcare Companies the Green Light
04:00pm, Friday, 22'nd Apr 2022
These Fool.com contributors see happy news in the future for Novavax, Axsome Therapeutics, and Novocure.
